Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

The full spectrum of opioid effects

Project description

Studying opioid response to personalise pain relief

Opioids are powerful painkillers, but addiction is a serious issue. Traditional studies look at average effects and often ignore individual differences. The ERC-funded SpectrO project will investigate why opioids relieve pain for some patients and not for others. It examines the full range of responses to opioids to understand the reasons behind their different effects. By using large data sets, genetic models, and N-of-1 trials with personalised dosing, SpectrO will offer reliable evidence on both extremes of opioid sensitivity. This work seeks to link group studies to clinical practice, improve personalised pain management, and guide public health strategies related to addiction.

Objective

Opioids are irreplaceable and effective analgesics– at the group level. However, clinicians still cannot predict how much pain relief each patient will achieve, nor who will develop addiction. By treating the variability of opioid effects as noise, the group-based efficacy studies fail to explain why opioids relieve pain in some people, but not in others. Here, I will turn the current approach on its head. By harnessing the valuable information inherent in opioids’ variable and diverse effects, I aim to achieve a breakthrough in our ability to predict individual patient responses to opioids and enable effective personalised pain treatment. SpectrO has three main objectives:

1) First, I will employ large-scale data to generate robust and reproducible evidence on the full spectrum of opioid effects and resolve key controversies in the opioid literature (WP1: comprehensive samples).

Next, I will hone in on each extreme of the opioid effects spectrum to:

2) Answer why opioid effects are so variable and diverse. A newly discovered human genetic knockout model affords unprecedented insights into human endogenous opioid function, far beyond the current state-of-the-art (WP2: opioid-insensitive sample).

3) Produce randomised controlled evidence at the individual level through a N-of-1 case series with double-blind dose titration for individual dose efficacy determination. WP3 represents a leap forward in opioid research, promising to close the gap between the group-based trials (which show no benefit of long-term opioids) and the clinical experience that some patients do benefit (opioid-sensitive sample).

My unique track record in leading large interdisciplinary opioid trials and conducting innovative literature syntheses lends feasibility to this ambitious project. SpectrO will set a new direction for opioid research, offering powerful new resources and methods to resolve key mechanistic questions and urgent public health issues on pain and addiction.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-COG

See all projects funded under this call

Host institution

UNIVERSITETET I OSLO
Net EU contribution
€ 2 323 358,50
Address
PROBLEMVEIEN 5-7
0313 Oslo
Norway
Region
Norge Oslo og Viken Oslo
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 323 358,50

Beneficiaries (2)